- Home
- TCRX vs MREO Comparison
TCRX vs MREO Comparison
Compare TCRX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | MREO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 52.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TCRX | MREO |
|---|---|---|
| Price | $1.01 | $0.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7.00 | $1.50 |
| AVG Volume (30 Days) | 574.3K | ★ 1.3M |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.28 | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | $500,000.00 |
| Revenue This Year | N/A | $6,756.00 |
| Revenue Next Year | $19.81 | $38.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $0.20 |
| 52 Week High | $2.57 | $2.94 |
Technical Indicators
Market Signals| Indicator | TCRX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 37.84 |
| Support Level | $0.90 | $0.32 |
| Resistance Level | $1.24 | $0.42 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 34.91 | 22.77 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).